Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT00655850
Completed
This study is being done to determine the overall progression-free survival (PFS) in patients with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC treated with metronomic chemotherapy plus Avastin. Also, currently there are no defined markers that predict for clinical benefit to Avastin. Preliminary studies show that there are several observations that support the concept of metronomic chemotherapy with or without the combination of an anti-angiogenic agen... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
06/19/2017
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
NCT01774851
Terminated
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2017
Locations: Not set, Birmingham, Alabama +20 locations
Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Register for Updates
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
NCT00789581
Completed
This is a randomized, Phase III, open-label, multicenter study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2017
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +69 locations
Conditions: Breast Cancer
Register for Updates
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
NCT00194792
Terminated
This phase II trial is studying how well giving hormone therapy together with combination chemotherapy before and after surgery works in treating patients with stage I-IIIA breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane and triptorelin pamoate may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy, such as capecitabine, methotrexate, vinorelbine ditartrate, and paclitaxel, work in different ways... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/09/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
NCT00454324
Terminated
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and Abraxane.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2017
Locations: University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Small Cell Lung Cancer
Register for Updates
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
NCT00511992
Completed
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2017
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
Register for Updates
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
NCT00111787
Completed
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of treatment and at the time of surgical resection will be examined for pathologic response and biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of 14 days of lapatinib monotherapy followed by 12 weeks... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2017
Locations: GSK Investigational Site, Miami, Florida +24 locations
Conditions: Neoplasms, Breast
Register for Updates
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00637897
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, docetaxel,, paclitaxel, and ixabepilone work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Paricalcitol may help chemotherapy drugs to kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This clinical trial is studying the best dose and best way to give paricalcitol and to see how well it works... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
05/25/2017
Locations: Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Breast Cancer
Register for Updates
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
NCT00856492
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Monoclonal antibodies, such as... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2017
Locations: Providence Cancer Center at Providence Hospital, Mobile, Alabama +365 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00280150
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by bloc... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/19/2017
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Lung Cancer
Register for Updates
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
NCT00662311
Terminated
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor ce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
NCT01778803
Completed
This is a Phase I/Ib, open-label, multicenter, dose-escalation trial of paclitaxel in combination with defactinib (VS-6063), a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. This clinical study is comprised of 2 parts: Phase I (Dose Escalation) and Phase Ib (Expansion). The purpose of this study is to assess assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063) when administered in combin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2017
Locations: Florida Cancer Specialists, Sarasota, Florida +2 locations
Conditions: Ovarian Cancer
Register for Updates